« China Brings the Heat on Innovation | Main | Rich Markets Lure Biotech's from Developing World Cures »

09/16/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0134876a10b6970c

Listed below are links to weblogs that reference Cost-Effectiveness and Health Care Policy:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

Today Adam Feuerstein reports in The Street that Medicare's questions surrounding Dendreon's Provenge (apprx $93,000 per patient) are sending its stock price tumbling - based on uncertainty of how govt will handle coverage/reimbursement
http://www.thestreet.com/story/10872332/1/dendreon-shares-roiled-by-medicare-questions.html

bigredbruce

More on this today (Sept 27th) from the PharmaGossip blog given the high cost of cancer treatments for fairly modest survival gains
http://pharmagossip.blogspot.com/2010/09/provenge-93000-for-four-extra-months.html

bigredbruce

Another good post on this topic relative to the US Health care policy from NYTimes March 2009
http://economix.blogs.nytimes.com/2009/03/13/cost-effectiveness-analysis-and-us-health-care/

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada